Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19247635 | Coralline Hydroxyapatite And Preparation Method Thereof | June 2025 | December 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 18991280 | PREPARATION METHOD FOR THREE-DIMENSIONAL GELATIN SCAFFOLD WITH INTERCONNECTED PORES AND APPLICATION THEREOF | December 2024 | January 2026 | Allow | 13 | 2 | 0 | No | No |
| 18954292 | IMPLANTS FOR CARTILAGE AND RELATED DEVICES AND METHODS | November 2024 | October 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18742182 | GROWTH FACTOR TRANSDUCED CELL-LOADED CERAMIC SCAFFOLD FOR BONE REGENERATION AND REPAIR | June 2024 | December 2025 | Allow | 18 | 2 | 0 | No | No |
| 18372975 | METHODS FOR FORMING STENTS MODIFIED WITH MATERIAL COMPRISING AMNION TISSUE | September 2023 | January 2026 | Allow | 28 | 2 | 0 | No | Yes |
| 18462292 | COMPOSITIONS USING IRON EXCIPIENTS AND THEIR USES INCLUDING FOR THE TREATMENT OF CANCER | September 2023 | June 2025 | Allow | 21 | 3 | 0 | No | No |
| 18350304 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | July 2023 | March 2026 | Allow | 32 | 4 | 0 | Yes | No |
| 18346288 | DEVICE FOR TRAPPING ABNORMAL MOTILE CELLS | July 2023 | December 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18305346 | NERVE CONDUIT LOADED WITH ADIPOSE-DERIVED STEM CELLS AND PREPARATION METHOD THEREOF | April 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18131345 | NERVE GROWTH SYSTEM | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18175502 | RESORBABLE NONWOVEN POUCHES FOR MEDICAL DEVICE IMPLANTS | February 2023 | June 2025 | Allow | 28 | 2 | 0 | No | No |
| 18106452 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | February 2023 | September 2025 | Allow | 31 | 3 | 0 | Yes | No |
| 18062584 | TEMPERATURE-SENSITIVE GEL MATERIAL COMBINATION, PREPARATION METHOD THEREFOR AND USE THEREOF | December 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18058909 | PARTICLE SUITABLE FOR THE MANUFACTURE OF AN IMPLANTABLE SOFT TISSUE ENGINEERING MATERIAL | November 2022 | March 2026 | Allow | 39 | 1 | 0 | Yes | No |
| 17996399 | Formulation comprising a phosphocalcic cement and a physical and/or covalent hydrogel of polysaccharides, printable and having ductile mechanical properties for bone regeneration/bone repair | October 2022 | March 2026 | Allow | 41 | 1 | 0 | Yes | No |
| 17996124 | POROUS NANOCOMPOSITE MEDICAL IMPLANT DEVICE | October 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17930469 | 3D PRINTED UV CROSSLINKING MASKS | September 2022 | February 2026 | Allow | 42 | 1 | 1 | No | No |
| 17759610 | COMPOSITION CONTAINING CURCUMIN COMPOUND, AND METHOD FOR PRODUCING SAME | July 2022 | February 2026 | Allow | 42 | 1 | 0 | Yes | No |
| 17860724 | Biomedical Implant Having Needle-Like Titania Nanorods | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17854555 | Biomedical Implant Having Conical-Tipped Titania Nanorods | June 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17636900 | INJECTABLE IN SITU PORE-FORMING HYDROGEL SYSTEM AND PREPARATION METHOD AND USE THEREOF | June 2022 | July 2023 | Allow | 17 | 2 | 0 | No | No |
| 17830804 | METHOD FOR REDUCING IMPERFECTIONS OF GLUTEUS | June 2022 | June 2025 | Abandon | 36 | 4 | 0 | Yes | No |
| 17776726 | GLYCERIN DISPERSION AND COSMETIC | May 2022 | November 2025 | Allow | 42 | 2 | 0 | No | No |
| 17776457 | FLUORINATED PHENYLACETIC ACID DERIVATIVES IN A WEED CONTROL METHOD | May 2022 | February 2025 | Allow | 33 | 1 | 1 | No | No |
| 17738047 | Systems And Methods For Delivering Active Agents | May 2022 | October 2025 | Allow | 41 | 4 | 0 | Yes | No |
| 17773914 | A COLLAGEN SCAFFOLD | May 2022 | February 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17770155 | PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17769042 | A BIODISSOLVABLE FILM FOR LOCALIZED AND EFFICIENT TREATMENT OF VULVODYNIA | April 2022 | March 2026 | Allow | 47 | 3 | 0 | Yes | No |
| 17719456 | DEVICES AND METHODS FOR IMPROVING THE GROWTH OF HOST TISSUE INTO AN ALLOGRAFT | April 2022 | April 2025 | Abandon | 36 | 4 | 1 | No | No |
| 17714594 | ANTIBACTERIAL IMPLANT COATING COMPOSITION, METHOD OF IMPLANT COATING AND ANTIBACTERIAL COATED IMPLANT | April 2022 | January 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17766376 | Long Acyl-Chain Phospholipid Oxygen Microbubbles for Treating Tumor Hypoxia | April 2022 | September 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17765839 | HERBICIDE COMPOSITION | April 2022 | August 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17753790 | HIGH LOAD FORMULATION CONTAINING A SULFOPOLYMER | March 2022 | November 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17693586 | INTERMITTENT CATHETERS | March 2022 | December 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17635291 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF METABOLIC DISEASES AND DISORDERS | February 2022 | February 2026 | Abandon | 48 | 2 | 1 | No | No |
| 17585509 | HYALURONIC ACID AND GELATIN-CONTAINING FORMULATIONS | January 2022 | May 2024 | Abandon | 27 | 3 | 0 | Yes | Yes |
| 17581679 | NOVEL BONE PUTTY COMPOSITIONS AND METHODS OF USE THEREOF | January 2022 | February 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17625835 | Microbe-Based Compositions for Restoring Soil Health and Controlling Pests | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17571446 | High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents | January 2022 | July 2024 | Abandon | 31 | 0 | 0 | No | No |
| 17544061 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM | December 2021 | December 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17544056 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17527839 | IMPLANT PELLETS AND METHODS FOR PERFORMING BONE AUGMENTATION AND PRESERVATION | November 2021 | September 2023 | Allow | 22 | 1 | 0 | No | No |
| 17514861 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM | October 2021 | September 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17514851 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM | October 2021 | March 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17502392 | COMPOSITION COMPRISING A DICARBONYL DERIVATIVE AND METHOD FOR STRAIGHTENING THE HAIR USING THIS COMPOSITION | October 2021 | January 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17442853 | COMPOSITIONS AND METHODS RELATING TO INSECTICIDES | September 2021 | September 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17477947 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | September 2021 | December 2023 | Allow | 26 | 3 | 1 | No | No |
| 17402357 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | August 2021 | December 2022 | Allow | 60 | 2 | 2 | Yes | No |
| 17400365 | NANOCOMPOSITES AND METHODS OF MAKING SAME | August 2021 | October 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17395985 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | August 2021 | January 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17365076 | NANOFIBER REINFORCEMENT OF ATTACHED HYDROGELS | July 2021 | March 2023 | Allow | 20 | 2 | 1 | No | No |
| 17327253 | ENDOSCOPE VISUAL FIELD-SECURING VISCOELASTIC COMPOSITION | May 2021 | March 2025 | Abandon | 46 | 6 | 1 | Yes | No |
| 17313274 | EXTENDED RELEASE DOSAGE FORMS OF PREGABALIN | May 2021 | November 2024 | Abandon | 43 | 3 | 0 | No | No |
| 17244958 | STERILIZING AGENTS, THEIR METHOD OF MANUFACTURE AND USES | April 2021 | May 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17240366 | LYOPHILIZED MOLDABLE IMPLANTS CONTAINING AN OXYSTEROL | April 2021 | October 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17237184 | NANOCOMPOSITES AND NANOAGENTS FOR DETECTION AND TREATMENT OF A TARGET OF INTEREST AND METHODS OF MAKING AND USING SAME | April 2021 | August 2025 | Allow | 51 | 3 | 1 | No | No |
| 17192072 | METAL OBJECT WITH ROUGHENED SURFACE AND METHOD OF PRODUCTION | March 2021 | November 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17266351 | OXYGEN-GENERATING CRYOGELS | February 2021 | February 2025 | Allow | 48 | 3 | 1 | No | No |
| 17148427 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP WITH RAPID RELEASE | January 2021 | December 2025 | Allow | 59 | 2 | 2 | Yes | No |
| 17143468 | METHODS AND COMPOSITIONS TO GRAFT BONE USING IRON EXCIPIENTS FOR CANCER TREATMENT | January 2021 | July 2024 | Allow | 42 | 9 | 1 | Yes | No |
| 17138703 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP | December 2020 | May 2022 | Allow | 16 | 3 | 1 | Yes | No |
| 17057016 | STIMULATION OF THE YIELD OF ONE OR MORE DESIRED COMPOUNDS PRODUCED BY A PLANT | November 2020 | June 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17098580 | SOLID FORMS FOR TISSUE REPAIR | November 2020 | September 2025 | Allow | 58 | 5 | 1 | Yes | No |
| 17096390 | Amorphous Silicon Oxide, Amorphous Silicon Oxynitride, and Amorphous Silicon Nitride Thin Films and Uses Thereof | November 2020 | June 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17077950 | POLYSACCHARIDE-POLYAMINE COPOLYMERS FOR REMOVAL OF PHOSPHATE | October 2020 | August 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17071102 | High Osmolarity Antimicrobial Composition Containing One or More Organic Solvents | October 2020 | August 2024 | Allow | 46 | 2 | 0 | No | No |
| 17069557 | ORAL TAXANE COMPOSITIONS AND METHODS | October 2020 | December 2023 | Allow | 38 | 5 | 0 | No | No |
| 17065727 | DRUG-IMPREGNATED ENCASEMENT | October 2020 | March 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17037830 | NANOCOMPOSITES, METHODS OF MAKING SAME, AND APPLICATIONS OF SAME FOR MULTICOLOR SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) DETECTIONS | September 2020 | August 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 17015700 | EXPANDABLE GASTRORETENTIVE DOSAGE FORM | September 2020 | January 2023 | Allow | 28 | 4 | 1 | Yes | No |
| 16966111 | BIOINK COMPOSITION FOR CARTILAGE REGENERATION, METHOD FOR MANUFACTURING CUSTOMIZED SCAFFOLD FOR CARTILAGE REGENERATION USING SAME, AND CUSTOMIZED SCAFFOLD FOR CARTILAGE REGENERATION MANUFACTURED USING MANUFACTURING METHOD | July 2020 | February 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16940740 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIEMETICS AND ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USING THE SAME FOR ANESTHESIOLOGICAL APPLICATIONS | July 2020 | October 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16931034 | Transcutaneous Intraosseous Devices and Methods for Manufacturing Thereof | July 2020 | September 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16927845 | BONE GRAFT COMPOSITION AND MANUFACTURING METHOD THEREOF | July 2020 | February 2025 | Allow | 55 | 5 | 1 | Yes | No |
| 16960379 | COLLAGEN PEPTIDE-CONTAINING POLYCAPROLACTONE MICROSPHERE FILLER AND PREPARATION METHOD THEREFOR | July 2020 | June 2025 | Abandon | 59 | 4 | 1 | No | No |
| 16918673 | IMPLANTS HAVING A DRUG LOAD OF AN OXYSTEROL AND METHODS OF USE | July 2020 | August 2021 | Allow | 14 | 2 | 0 | No | No |
| 16915025 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | June 2020 | November 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16903435 | ANTI-HEMORRHAGING COMPOSITIONS | June 2020 | September 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16899363 | GROWTH FACTOR TRANSDUCED CELL-LOADED CERAMIC SCAFFOLD FOR BONE REGENERATION AND REPAIR | June 2020 | July 2024 | Allow | 50 | 4 | 1 | No | No |
| 16770091 | FIBER BUNDLE REINFORCED BIOCOMPOSITE MEDICAL IMPLANTS | June 2020 | May 2025 | Abandon | 60 | 5 | 0 | No | No |
| 16887478 | OSTEOIMPLANT COMPRISING AN INSOLUBLE FIBROUS POLYMER | May 2020 | June 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16882868 | NOVEL OCCLUSIVE FORMULATIONS | May 2020 | November 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16765977 | COMPOSITIONS AND METHODS FOR ADMINISTERING A YAP1/WWRT1 INHIBITING COMPOSITION AND A GLS1 INHIBITING COMPOSITION | May 2020 | September 2023 | Abandon | 40 | 3 | 1 | No | No |
| 16874313 | 3D-Porous Hybrid Anti-Inflammatory Nanoscaffold for Drug Delivery and Tissue Engineering | May 2020 | March 2025 | Allow | 58 | 6 | 1 | Yes | No |
| 16763753 | SYSTEMS AND METHODS FOR RECONSTRUCTION OF NERVE DEFECTS | May 2020 | November 2022 | Allow | 30 | 2 | 0 | No | No |
| 16868178 | LYOPHILIZED MOLDABLE IMPLANTS CONTAINING AN OXYSTEROL | May 2020 | December 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16864373 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | May 2020 | December 2021 | Abandon | 19 | 2 | 1 | Yes | No |
| 16863836 | THERMALLY NEUTRAL INHALATION GAS COMPOSITION | April 2020 | September 2022 | Abandon | 29 | 2 | 0 | Yes | No |
| 16850037 | Systems And Methods For Delivering Active Agents | April 2020 | May 2022 | Abandon | 25 | 1 | 1 | Yes | No |
| 16755811 | INJECTABLE AND EXPANDABLE COMPOSITION, DEVICES, KITS, METHODS AND USES THEREOF | April 2020 | September 2021 | Allow | 17 | 0 | 0 | Yes | No |
| 16652357 | EYE MAKE-UP COSMETIC COMPOSITION COMPRISING ACRYLATE-BASED COPOLYMER | March 2020 | May 2022 | Abandon | 25 | 3 | 1 | No | No |
| 16650555 | PARTICLE SUITABLE FOR THE MANUFACTURE OF AN IMPLANTABLE SOFT TISSUE ENGINEERING MATERIAL | March 2020 | June 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16795174 | Fast Acting Inhibitor of Gastric Acid Secretion | February 2020 | May 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16793470 | VASCULAR GRAFT AND METHODS FOR SEALING A VASCULAR GRAFT | February 2020 | July 2024 | Abandon | 53 | 6 | 1 | Yes | No |
| 16789477 | RODENT REPELLING SPRAY POLYURETHANE FOAM SYSTEM | February 2020 | October 2021 | Abandon | 20 | 3 | 0 | No | No |
| 16780596 | UNIAXIALLY-ALIGNED NANOFIBER SCAFFOLDS AND METHODS FOR PRODUCING AND USING SAME | February 2020 | November 2024 | Allow | 58 | 5 | 1 | Yes | No |
| 16746460 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | January 2020 | December 2020 | Allow | 11 | 1 | 0 | No | No |
| 16743700 | SYSTEMS TO PROMOTE HEALING AT A SITE OF A MEDICAL DEVICE | January 2020 | November 2023 | Abandon | 46 | 3 | 1 | No | No |
| 16617415 | IONIC-DOPED COMPOSITION METHODS AND USES THEREOF | November 2019 | April 2023 | Abandon | 40 | 3 | 0 | No | No |
| 16616418 | FORMATION OF STABLE CARTILAGE | November 2019 | October 2020 | Allow | 11 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAGOPIAN, CASEY SHEA.
With a 8.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HAGOPIAN, CASEY SHEA works in Art Unit 1617 and has examined 540 patent applications in our dataset. With an allowance rate of 58.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner HAGOPIAN, CASEY SHEA's allowance rate of 58.0% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HAGOPIAN, CASEY SHEA receive 2.32 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HAGOPIAN, CASEY SHEA is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +41.2% benefit to allowance rate for applications examined by HAGOPIAN, CASEY SHEA. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.6% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.1% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 60.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 64.7% of appeals filed. This is in the 45% percentile among all examiners. Of these withdrawals, 59.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 64.8% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 52% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.